Polymorphs of LNnT
A crystalline LNnT polymorph IV, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 8.16, 15.41, 39.14, 23.77, 7.77 and 31.15 2Θ angles, and a crystalline LNnT polymorph V, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 9.15, 10.26, 19.68, 26.06, 20.61 and 1 1.89 2Θ angles, are provided.
1. A crystalline LNnT polymorph IV, wherein the crystalline LNnT polymorph IV displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 8.16 2Θ, 15.41 2Θ, 39.14 2Θ, 23.77 2Θ, and 7.77 2Θ.
2. The crystalline LNnT polymorph IV of claim 1 , wherein the crystalline LNnT polymorph IV is substantially pure.
3. The crystalline LNnT polymorph IV of claim 1 , wherein the crystalline LNnT polymorph IV is substantially free from organic solvent.
4. The crystalline LNnT polymorph IV of claim 1 for use as a pharmaceutical agent.
5. A pharmaceutical composition comprising the crystalline LNnT polymorph IV of claim 1 and one or more pharmaceutically acceptable carriers.
6. A nutritional formulation comprising the crystalline LNnT polymorph IV of claim 1 .
7. The nutritional formulation of claim 6 , wherein the nutritional formulation is an infant formula.
8. The nutritional formulation of claim 6 , wherein the nutritional formulation is a food supplement.
9. The food supplement of claim 8 , wherein the food supplement is a digestive health functional food.
10. The crystalline LNnT polymorph IV of claim 1 , wherein the crystalline LNnT polymorph IV displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 8.16 2Θ, 15.41 2Θ, 39.14 2Θ, 23.77 2Θ, 7.77 2Θ, and 31.15 2Θ.
11. A crystalline LNnT polymorph V, wherein the crystalline LNnT polymorph V displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 9.15 2Θ, 10.26 2Θ, 19.68 2Θ, 26.06 2Θ, and 20.61 2Θ.
12. A method for producing the crystalline LNnT polymorph IV of claim 1 , wherein an aqueous solution of greater than 25 w/w % LNnT is stored at 2-25° C.
13. The crystalline LNnT polymorph IV of claim 11 , wherein the crystalline LNnT polymorph V displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 9.15 2Θ, 10.26 2Θ, 19.68 2Θ, 26.06 2Θ, 20.61 2Θ, and 11.89 2Θ.
14. The crystalline LNnT polymorph V of claim 11 , wherein the crystalline LNnT polymorph V is substantially pure.
15. The crystalline LNnT polymorph V of claim 11 , wherein the crystalline LNnT polymorph V is substantially free from organic solvent.
16. The crystalline LNnT polymorph V of claim 11 for use as a pharmaceutical agent.
17. A pharmaceuticalcomposition comprising the crystalline LNnT polymorph V of claim 11 and one or more pharmaceutically acceptable carriers.
18. A nutritional formulation comprising the crystalline LNnT polymorph V of claim 11 .
19. A method for producing the crystalline LNnT polymorph V of claim 11 , wherein the crystalline LNnT polymorph IV of claim 1 is dried under vacuum at 40-60° C.